AN2 Therapeutics Secures Grant to Advance TB and Malaria Treatment

AN2 Therapeutics, Inc. has secured a continuation of its research grant from the Bill & Melinda Gates Foundation to develop boron-containing small molecules targeting tuberculosis (TB) and malaria. The grant aims to discover novel inhibitors of aminoacyl-tRNA synthetases using AN2’s proprietary boron chemistry platform. This initiative seeks to address drug resistance and reduce treatment duration for TB and malaria, diseases responsible for nearly 2 million deaths annually worldwide.

Eric Easom, Co-Founder, President, CEO, and Chairman of AN2 Therapeutics, expressed gratitude for the foundation's ongoing support, emphasizing the potential of their boron chemistry platform in addressing unmet needs in infectious diseases. The grant will bolster efforts to develop new therapies leveraging AN2's expertise in boron chemistry, which has previously led to the discovery of compounds such as epetraborole, tavaborole, and ganfeborole, currently in development for various infectious diseases.

AN2 Therapeutics is a biopharmaceutical company focused on creating novel small molecule therapeutics from its boron chemistry platform, with a pipeline targeting Chagas disease, nontuberculous mycobacteria (NTM), and melioidosis, among others.

The continuation of this grant represents a significant step in advancing AN2's research and development capabilities, potentially leading to breakthroughs in the treatment of TB and malaria. The impact of this funding could be substantial, as it supports the development of innovative solutions to combat these global health challenges.